A small molecule shows strong activity against a cancer-related target. Follow-up experiments confirm the initial result, and the chemistry team begins developing related compounds. Yet one question remains: can the molecule achieve the exposure needed to make that activity meaningful?

Potency provides only part of the answer. Researchers also need to understand how a compound crosses biological barriers, whether it remains intact in relevant biological environments, and which properties may limit its further development.

For small-molecule oncology programs, permeability testing and plasma stability assessment offer complementary information. Evaluating them within a broader ADME strategy can help teams decide which compounds deserve additional investigation.

Permeability Adds Context to Biological Activity

For a molecule directed at an intracellular target, reaching the relevant cellular compartment is a prerequisite for target engagement. Permeability measurements help characterize one part of that access problem.

Different assays answer different questions. The parallel artificial membrane permeability assay, or PAMPA, examines passive permeation across an artificial membrane. Cell-based models introduce a biological barrier and, depending on the model and experimental design, can help investigate directional transport. These results require interpretation alongside the assay's intended purpose and limitations.

In an oncology discovery program, compound permeability analysis can support the investigation of differences between biochemical and cellular activity. However, a permeability result alone cannot establish intracellular target engagement or predict tumor exposure.

For example, imagine two analogs with similar activity against a purified enzyme but different effects in cells. Permeability becomes one possible explanation to investigate alongside other factors, such as compound stability and the biological context of the cellular assay.

The useful outcome is a more focused follow-up experiment.

Plasma Stability Examines a Different Vulnerability

A compound may cross a membrane effectively yet undergo degradation in plasma. Plasma stability testing investigates whether the parent molecule remains intact during incubation under defined conditions.

An experimental study of high-throughput plasma stability testing demonstrated its usefulness for identifying labile structural features and prioritizing compounds for subsequent studies. The researchers also examined variables affecting assay results, including incubation conditions and plasma batch differences.

A plasma stability assessment therefore addresses a question that permeability testing leaves open: does the compound persist in this biological matrix?

The distinction matters when interpreting an apparently promising profile. Good membrane permeability does not compensate automatically for rapid plasma degradation. Equally, plasma stability does not establish that a compound can reach its intended target.

Study reports should make the experimental context clear, including the plasma species, incubation period, and analytical endpoint. This helps researchers compare compounds without treating measurements from different conditions as interchangeable.

Read the Results Together

Consider a hypothetical series of three oncology compounds.

One analog has strong biochemical potency but weak permeability. A second crosses the assay barrier more readily but loses parent compound rapidly in plasma. A third has slightly weaker potency while performing more consistently across both assessments.

These profiles suggest different questions for the chemistry team. The first may warrant investigation of the properties limiting membrane passage. The second may prompt examination of structural features associated with instability. The third may justify further characterization to determine whether its broader profile supports progression.

This example does not establish a universal ranking. The preferred compound depends on the target, intended route of administration, exposure requirements, and other project-specific evidence.

It does show why a single favorable measurement can be misleading when separated from the rest of the dataset.

Build an ADME Plan Around the Next Decision

Early screening works best when each assay supports a defined development question. Research from NCATS illustrates this approach: solubility, permeability, and microsomal stability are evaluated together within its Tier I ADME screening framework, providing complementary information for compound assessment.

For an oncology team, the next decision might be whether to synthesize additional analogs, investigate an unexpected activity difference, or select compounds for pharmacokinetic studies.

An integrated in vitro ADME evaluation provides a useful framework for organizing those questions. The assay selection should follow the project's needs, with results reviewed together rather than reduced to isolated pass-or-fail labels.

The aim is to identify a compound whose biological activity and disposition properties support the same development goal. Bringing permeability and plasma stability into that discussion early gives researchers a clearer basis for choosing their next experiment.